title: Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
abstract: A 67-year-old man with AML, who had a 21-year history of psoriasis without remission, received a reduced-intensity transplantation from an HLA-identical sibling. The preparative regimen consisted of busulfan and fludarabine. Graft-versus-host-disease (GVHD) prophylaxis was cyclosporine and methotrexate. Psoriasis was completely resolved on day 18. The subsequent clinical course was uneventful until day 42, when psoriasis recurred at the same sites as before RIST. Peripheral blood examined on day 63 showed mixed chimerism with 54% recipient type. Cyclosporine was rapidly tapered off over the next 2 weeks. On day 90, 100% donor-type chimerism was confirmed. Subsequently, psoriasis improved simultaneously with the occurrence of mucositis and rash as a manifestation of GVHD. Scattered erythematous patches of psoriasis disappeared again by day 105. We initiated 0.5 mg/kg prednisolone on day 119, and resumed cyclosporine on day 133. At 7 months after RIST, he still suffers from chronic GVHD, but his psoriasis remains in remission for the first time in 21 years. The anti-psoriasis effect of the conditioning is mild and transient, while the graft-versus-autoimmunity effect, related to the induction of complete donor-type chimerism and GVHD, is more profound and persisting. A graft-versus-autoimmunity effect lies in the delicate balance between alloimmunity and immunosuppressant used for GVHD prophylaxis/treatment.
authors.affiliation: Hematopoietic Stem Cell Transplant Unit, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Kojima
authors.forename: M
authors.initials: M
authors.lastname: Kami
authors.forename: S-W
authors.initials: SW
authors.lastname: Kim
authors.forename: N
authors.initials: N
authors.lastname: Murashige
authors.forename: Y
authors.initials: Y
authors.lastname: Kishi
authors.forename: A
authors.initials: A
authors.lastname: Hori
authors.forename: O
authors.initials: O
authors.lastname: Imataki
authors.forename: T
authors.initials: T
authors.lastname: Hamaki
authors.forename: M
authors.initials: M
authors.lastname: Sakiyama
authors.forename: S
authors.initials: S
authors.lastname: Masuo
authors.forename: Y
authors.initials: Y
authors.lastname: Fujisawa
authors.forename: A
authors.initials: A
authors.lastname: Makimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Heike
authors.forename: R
authors.initials: R
authors.lastname: Tanosaki
authors.forename: Y
authors.initials: Y
authors.lastname: Takaue
mesh_terms: D000368:Aged; D016572:Cyclosporine / Q000494:pharmacology; D006086:Graft vs Host Disease / Q000473:pathology; D020350:Graft vs Tumor Effect; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000494:pharmacology; D011565:Psoriasis / Q000628:therapy; D012074:Remission Induction; D013997:Time Factors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000379:methods*
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D008727:Methotrexate